Rich has led the Neurotech team since March, 2016. He originally joined Neurotech in July, 2007 as the Company’s Chief Financial Officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers.
At Point he was a founding member of the Company and involved in taking the company public and successfully completed several private and public equity offerings. Prior to Point he served as Vice President, Chief Financial Officer at Immulogic Pharmaceutical, Inc., a publicly traded biotechnology company developing treatments for immunological-based disorders. At Immulogic he was involved in completing multiple licensing deals and several public equity offerings.
Rich also served as a Trustee for the New England College of Optometry from 1995 to 2022 and served as Chair of the Finance and Business Affairs Committee and member of the Executive Committee for over 15 years. His early career was spent in senior management financial and treasury positions at Dennison Manufacturing Company and he began his career at the public accounting firm of Coopers and Lybrand, LLC. Rich has a BS in Business Administration from Northeastern University in Boston, Massachusetts.